FRM
FDMT icon

Fox Run Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Fox Run Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,309
Closed -$68.6K – 1005
2024
Q4 		$68.6K Buy
+12,309
New +$96.6K 0.01% 825
2023
Q4 		– Sell
-12,162
Closed -$155K – 816
2023
Q3 		$155K Buy
+12,162
New +$203K 0.05% 597

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fox Run Management's FDMT Position: Q1 2025 in Review

Fox Run Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 12,309 shares — an estimated $68.6K sold.

Fox Run Management first reported a position in FDMT in Q3 2023 and held it in 2 quarters. The position peaked at $155K in Q3 2023. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

  • Fox Run Management reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Fox Run Management sold 12,309 4D Molecular Therapeutics shares in Q1 2025, an estimated $68.6K.
  • Fox Run Management first reported a position in 4D Molecular Therapeutics in Q3 2023 and held it in 2 quarters.
  • Fox Run Management's 4D Molecular Therapeutics position peaked at $155K in Q3 2023.
  • 125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on Fox Run Management's 13F filing for Q1 2025, filed 13 May 2025.